|
Ethics Approval for Phase I/II UTI Trial Expansion
|
29 June 2023 at 2:10pm
|
|
Change of Director's Interest Notice - J Graham
|
26 June 2023 at 4:20pm
|
|
DFI Clinical Trial Outpatient Nurses Appointed
|
29 May 2023 at 11:15am
|
|
WA Government Sponsorship for BIO Korea 2023
|
8 May 2023 at 10:05am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 April 2023 at 2:25pm
|
|
Ethics Approval to Start Phase I/II (I.V.) Clinical Trial
|
17 April 2023 at 10:45am
|
|
RECCE Trademark Registered - Israel
|
12 April 2023 at 10:50am
|
|
New Family 4 Patent to be Granted for RECCE Anti-Infectives
|
11 April 2023 at 8:50am
|
|
Recce Receives Further A$973,144 R&D Advance
|
4 April 2023 at 10:35am
|
|
Corporate Presentation - WI Emergence 2023
|
23 March 2023 at 10:45am
|
|
Appendix 4D and Interim Financial Report
|
27 February 2023 at 6:25pm
|
|
Investor Presentation - Spark Plus Biotech Day
|
24 February 2023 at 11:25am
|
|
Recce Selects CMAX for Phase I/II UTI Clinical Trial
|
20 February 2023 at 10:05am
|
|
Cleansing Statement
|
14 February 2023 at 2:40pm
|
|
Application for quotation of securities - RCE
|
14 February 2023 at 2:30pm
|
|
RECCE Trademark Registered - Hong Kong
|
2 February 2023 at 10:50am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 January 2023 at 1:50pm
|
|
A$6.21m Received from R&D Rebate Payments
|
25 January 2023 at 10:50am
|
|
Cleansing Statement
|
11 January 2023 at 5:45pm
|
|
Application for quotation of securities - RCE
|
11 January 2023 at 5:45pm
|
|
JP Morgan Healthcare Conference
|
10 January 2023 at 12:45pm
|
|
Australian Patent to be Granted for RECCE Anti-Infectives
|
10 January 2023 at 10:30am
|
|
Anti-Infective Research Unit est. at Murdoch Children's
|
15 December 2022 at 12:20pm
|
|
Approval to Start Phase I/II Diabetic Foot Ulcer Study
|
9 December 2022 at 10:30am
|
|
Trading Halt
|
7 December 2022 at 1:15pm
|
|
Pause in Trading
|
7 December 2022 at 1:10pm
|
|
Change of Director's Interest Notice - A McKeough
|
15 November 2022 at 6:00pm
|
|
Notification regarding unquoted securities - RCE
|
15 November 2022 at 5:55pm
|
|
Constitution
|
14 November 2022 at 7:05pm
|
|
Results of Meeting
|
14 November 2022 at 4:45pm
|
|
AGM Presentation
|
14 November 2022 at 2:00pm
|
|
Investor Presentation - Spark Plus Healthcare Day
|
3 November 2022 at 10:45am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 October 2022 at 12:10pm
|
|
Anti-Infective Portfolio Update and Webinar details
|
19 October 2022 at 10:40am
|
|
Pause in Trading
|
19 October 2022 at 10:20am
|
|
R327 COVID Study Update
|
18 October 2022 at 11:10am
|
|
Pause in trading
|
18 October 2022 at 10:20am
|
|
Notice of Annual General Meeting/Proxy Form
|
14 October 2022 at 3:10pm
|
|
Expansion and Acceleration of Clinical Programs
|
27 September 2022 at 10:25am
|
|
2022 Annual General Meeting
|
21 September 2022 at 2:05pm
|
|
Cleansing Statement
|
15 September 2022 at 2:10pm
|
|
Application for quotation of securities - RCE
|
15 September 2022 at 2:10pm
|
|
Recce Delivers Opening R&D Address at World AMR Congress
|
7 September 2022 at 10:25am
|
|
RCE Appoints Dr John Prendergast as Executive Chairman
|
5 September 2022 at 10:30am
|
|
Initial Director's Interest Notice - A McKeough
|
1 September 2022 at 12:30pm
|
|
Recce Appoints Alistair McKeough to Board of Directors
|
1 September 2022 at 12:25pm
|
|
Appendix 4G
|
31 August 2022 at 4:50pm
|
|
Annual Report to shareholders
|
31 August 2022 at 4:40pm
|
|
Appendix 4E
|
31 August 2022 at 4:40pm
|
|
Cleansing Statement
|
22 August 2022 at 4:40pm
|
Recce Pharmaceuticals Ltd